

ATMPs for the next 15 years

Jacquelyn Awigena-Cook, BMS

The Road Ahead for ATMPs in Europe

2024

Rapid pace of science and likely increase in product complexity in the future will require flexibility

- ATMPs targeting indications beyond haematology-oncology & rare diseases
- Increase in global access to ATMPs facilitated by regulatory convergence and harmonization efforts
- Sustainability of long-term follow-up where more ATMPs become available
- Timely implementation of improvements in EU General Pharma Legislation
 - Future proof definitions and regulatory mechanisms
 - Streamlining of structures and processes while retaining expertise
- Opportunity to increase innovation and R&D investment in EU



| 2024 | Clinical Trials (Snapshot Value) |
|---------------|-------------------------------------|
| North America | 974 |
| Asia Pacific | 784 |
| Europe | 341 |
| Total | 1,851* |

Source: [ARM August-2024-Sector-Snapshot](#)

2039